Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Ocular Therapeutix (OCUL) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $27.5 million.

  • Ocular Therapeutix's Accumulated Depreciation & Amortization rose 1645.23% to $27.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $27.5 million, marking a year-over-year increase of 1645.23%. This contributed to the annual value of $27.5 million for FY2025, which is 1645.23% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Accumulated Depreciation & Amortization of $27.5 million as of Q4 2025, which was up 1645.23% from $23.6 million recorded in Q4 2024.
  • Ocular Therapeutix's Accumulated Depreciation & Amortization's 5-year high stood at $27.5 million during Q4 2025, with a 5-year trough of $15.2 million in Q4 2021.
  • Its 5-year average for Accumulated Depreciation & Amortization is $20.8 million, with a median of $20.3 million in 2023.
  • As far as peak fluctuations go, Ocular Therapeutix's Accumulated Depreciation & Amortization soared by 1893.48% in 2021, and later skyrocketed by 1361.87% in 2022.
  • Over the past 5 years, Ocular Therapeutix's Accumulated Depreciation & Amortization (Quarter) stood at $15.2 million in 2021, then grew by 13.62% to $17.3 million in 2022, then grew by 17.26% to $20.3 million in 2023, then increased by 16.64% to $23.6 million in 2024, then grew by 16.45% to $27.5 million in 2025.
  • Its last three reported values are $27.5 million in Q4 2025, $23.6 million for Q4 2024, and $20.3 million during Q4 2023.